HC Wainwright Has Negative Estimate for PBLS FY2026 Earnings

Parabilis Medicines logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright lowered its FY2026 EPS estimate for Parabilis Medicines to a loss of $2.12 per share from a projected loss of $2.10, while maintaining its Buy rating and $40 price target.
  • Parabilis reported a quarterly loss of $0.36 per share, beating the consensus estimate of a $0.40 loss; revenue was $2.11 million.
  • Analyst sentiment remains broadly positive: MarketBeat reports a Moderate Buy consensus rating and an average price target of $40.80.
  • Five stocks we like better than Parabilis Medicines.

Parabilis Medicines, Inc. (NASDAQ:PBLS - Free Report) - Stock analysts at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for shares of Parabilis Medicines in a report issued on Friday, November 13th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($2.12) for the year, down from their prior forecast of ($2.10). HC Wainwright has a "Buy" rating and a $40.00 price target on the stock. The consensus estimate for Parabilis Medicines' current full-year earnings is ($2.60) per share. HC Wainwright also issued estimates for Parabilis Medicines' Q4 2026 earnings at ($0.37) EPS, Q1 2027 earnings at ($0.39) EPS, Q2 2027 earnings at ($0.40) EPS, Q3 2027 earnings at ($0.42) EPS, Q4 2027 earnings at ($0.44) EPS and FY2027 earnings at ($1.66) EPS.

Other equities analysts have also recently issued research reports about the stock. Canaccord Genuity Group assumed coverage on shares of Parabilis Medicines in a research note on Monday, November 9th. They issued a "buy" rating and a $39.00 price target on the stock. Weiss Ratings cut shares of Parabilis Medicines from a "sell (d+)" rating to a "sell (d)" rating in a report on Monday, November 2nd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $40.80.

View Our Latest Report on Parabilis Medicines

Parabilis Medicines Stock Up 0.1%

Shares of NASDAQ:PBLS opened at $28.45 on Tuesday. The firm's fifty day moving average is $30.63. Parabilis Medicines has a 1-year low of $22.66 and a 1-year high of $42.49.

Parabilis Medicines (NASDAQ:PBLS - Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.04. The company had revenue of $2.11 million during the quarter.

Hedge Funds Weigh In On Parabilis Medicines

Hedge funds have recently modified their holdings of the stock. Alphabet Inc. bought a new stake in shares of Parabilis Medicines in the 2nd quarter worth about $134,647,000. General Catalyst Group Management LLC purchased a new stake in shares of Parabilis Medicines during the 2nd quarter valued at about $43,818,000. WINTON GROUP Ltd purchased a new stake in shares of Parabilis Medicines during the 2nd quarter valued at about $955,000. Squarepoint Ops LLC bought a new position in shares of Parabilis Medicines in the 2nd quarter valued at about $1,327,000. Finally, ICONIQ Capital LLC bought a new position in shares of Parabilis Medicines in the 2nd quarter valued at about $9,580,000.

About Parabilis Medicines

(Get Free Report)

Parabilis Medicines is a clinical-stage biopharmaceutical company developing medicines for diseases driven by proteins that have been difficult to target with conventional drugs. Its research focuses on macrocyclic peptides designed to address challenging protein interactions, including targets relevant to cancer. The company uses its proprietary Helicon platform to design these peptide-based drug candidates. Parabilis is based in Cambridge, Massachusetts, and was formerly known as Peptone. Parabilis was founded by Gregory Verdine, who serves as the company's chief executive officer.

Featured Stories

Earnings History and Estimates for Parabilis Medicines (NASDAQ:PBLS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Parabilis Medicines Right Now?

Before you consider Parabilis Medicines, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Parabilis Medicines wasn't on the list.

While Parabilis Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines